Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tiziana Life Sciences PLC

1.55
+0.13009.15%
Post-market: 1.54-0.0100-0.65%19:56 EDT
Volume:1.05M
Turnover:1.66M
Market Cap:172.77M
PE:-13.94
High:1.64
Open:1.52
Low:1.47
Close:1.42
Loading ...

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

THOMSON REUTERS
·
18 Feb

3 Promising US Penny Stocks With Market Caps Over $20M

Simply Wall St.
·
12 Feb

Tiziana announces TV interview with AD patient dosed with foralumab

TIPRANKS
·
11 Feb

Tiziana Life Sciences Announces Tv Interview With First Patient Dosed With Moderate Alzheimer’s Disease

THOMSON REUTERS
·
11 Feb

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease

GlobeNewswire
·
11 Feb

Tiziana Life Sciences Shares Higher on Positive Results for Spinal Cord Injury Treatment

Dow Jones
·
24 Jan

Tiziana Life Sciences' Foralumab Demonstrates Motor Function Improvement in Preclinical Spinal Cord Injury Studies

MT Newswires Live
·
24 Jan

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-Cd3

THOMSON REUTERS
·
24 Jan

Tiziana Life Sciences Says it Has No Immediate Capital Raising Plans; Shares Fall

MT Newswires Live
·
23 Jan

Tiziana Life Sciences Not to Engage in Capital Raising Activities for the Immediate Future

THOMSON REUTERS
·
23 Jan

Tiziana Life Sciences not to engage in capital raising activities for the immediate future

GlobeNewswire
·
23 Jan

BRIEF-Tiziana Announces Discovery Of New Immune Biomarkers In Multiple Sclerosis Patients Treated With Nasal Foralumab

Reuters
·
23 Jan

Tiziana Life Sciences announces discovery of new immune biomarkers

TIPRANKS
·
23 Jan

Tiziana Life Sciences Ltd - Gene Expression Changes Detected Three Months After Foralumab Dosing

THOMSON REUTERS
·
23 Jan

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated With Nasal Foralumab

THOMSON REUTERS
·
23 Jan

3 Penny Stocks In US With Market Caps Below $300M

Simply Wall St.
·
13 Jan

BRIEF-Tiziana Announces Reduction Of Side Effects Commonly Seen With Discontinuation Of GLP-1 Agonists With Nasal Anti-CD3

Reuters
·
10 Jan

Tiziana Life Sciences announces findings on nasal anti-CD3 monoclonal antibody

TIPRANKS
·
10 Jan

Tiziana Life Sciences: Reduction of Side Effects Seen With Discontinuation of Glp-1 Agonists With Nasal Anti-Cd3

THOMSON REUTERS
·
10 Jan

Tiziana Life Sciences Ltd - FDA Allows Additional 20 Patients in Foralumab Expanded Access Program

THOMSON REUTERS
·
10 Jan